Hepatic Encephalopathy Diagnosis: A Comprehensive Guide for Automotive Repair Experts

Introduction

Hepatic encephalopathy is a complex neuropsychiatric syndrome arising from liver dysfunction, leading to an accumulation of neurotoxic substances in the bloodstream. It is essential to understand that hepatic encephalopathy diagnosis is one of exclusion, requiring careful differentiation from other conditions presenting with similar neurological symptoms. This condition manifests across a spectrum, from subtle cognitive impairments to severe confusion, marked personality changes, disorientation, lethargy, and ultimately, coma. Hepatic encephalopathy episodes are frequently triggered by factors such as infections, electrolyte imbalances, or gastrointestinal bleeding, and can occur in the context of both acute and chronic liver disease, as well as congenital or acquired portosystemic shunts. The diagnostic process relies heavily on clinical evaluation, ruling out alternative diagnoses, and employing neuroimaging when necessary. Management strategies are centered on identifying and managing precipitating factors, providing supportive care, and reducing ammonia levels through pharmacological interventions like lactulose and rifaximin, among other therapies.

For automotive repair experts who may encounter individuals experiencing medical emergencies or seeking clarity on health conditions affecting driving ability and cognitive function, understanding conditions like hepatic encephalopathy is crucial. This article provides an in-depth exploration of hepatic encephalopathy diagnosis, emphasizing the key diagnostic tools, including psychometric assessments, neuroimaging techniques, and laboratory evaluations that are critical in distinguishing hepatic encephalopathy from other neurological disorders. We will also highlight the importance of recognizing and managing precipitating factors that can trigger this condition. Furthermore, this discussion underscores the vital role of collaborative care among healthcare professionals to optimize patient outcomes, address treatment adherence, educate caregivers, and prevent recurrence. Ultimately, this resource aims to equip healthcare providers with the knowledge and skills necessary for accurate hepatic encephalopathy diagnosis, effective management, and preventative strategies, leading to improved patient quality of life and reduced mortality.

Etiology of Hepatic Encephalopathy

Hepatic encephalopathy can develop as a consequence of underlying liver disease or due to portosystemic shunts, such as transjugular intrahepatic portosystemic shunt (TIPS) or spontaneous shunts. In cases related to liver disease, the liver’s impaired function is the primary issue. Conversely, portosystemic shunts redirect portal circulation to the systemic circulation, bypassing the liver and resulting in the accumulation of toxic metabolites in the bloodstream.⁸ Acute liver failure, a rapid and severe decline in liver function, can be triggered by viral hepatitis, exposure to hepatotoxins like acetaminophen, or ischemic liver injury, such as in septic shock. Chronic liver failure, often progressing to cirrhosis, can stem from a variety of causes, including alcoholic cirrhosis, chronic viral hepatitis B or C, nonalcoholic fatty liver disease, hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency. Therefore, the development of hepatic encephalopathy is context-dependent and can occur in a wide range of clinical scenarios determined by the underlying etiology.

In some instances, hepatic encephalopathy can occur in the absence of significant liver dysfunction. This is observed in congenital portosystemic shunts or extrahepatic portal vein obstruction with shunting, where the liver is bypassed by systemic circulation. This bypass leads to hyperammonemia and subsequent neurological symptoms. Acute liver failure is characterized by a sudden and severe loss of liver function, typically without pre-existing portosystemic shunting, and is associated with markedly elevated ammonia levels and severe cerebral edema. In cirrhosis, hepatic encephalopathy can manifest with or without significant portosystemic shunting and is frequently linked to hyperammonemia, although the correlation between ammonia levels and symptom severity is not always straightforward. Understanding the etiological classification is crucial for effective hepatic encephalopathy diagnosis and management.

In patients with cirrhosis, several factors can precipitate hepatic encephalopathy, including:

• Gastrointestinal bleeding (e.g., acute variceal bleeding)
• Constipation
• Infections
• Dehydration (resulting from fluid restriction, diuretics, diarrhea, vomiting, or excessive paracentesis)
• Electrolyte imbalances (e.g., hyponatremia and hypokalemia)
• Alcohol use disorder
• Medications (e.g., benzodiazepines, opioids, and nonsteroidal anti-inflammatory drugs [NSAIDs])
• Kidney dysfunction and azotemia

Furthermore, hepatic encephalopathy can complicate 30% to 50% of cases in cirrhosis patients undergoing TIPS procedures. However, advancements in techniques, such as the use of smaller stents and improved patient selection, have helped to reduce this incidence.⁸, ⁹, ¹⁰ Spontaneous portosystemic shunts, which occur when fetal shunt pathways between the portal and systemic circulation reopen due to cirrhosis, can also significantly contribute to the development of hepatic encephalopathy. Over time, these shunts can increase in volume, leading to a decline in portal circulation and worsening liver failure.¹¹

Epidemiology of Hepatic Encephalopathy

Epidemiological studies provide valuable insights into the prevalence and risk of hepatic encephalopathy, which is crucial for understanding the scope of this condition and its impact on public health. A population-based study estimated that approximately 44% of individuals with cirrhosis may develop hepatic encephalopathy within a 5-year period.¹² Another study, involving over 9000 newly diagnosed cirrhosis patients, indicated that about one-third had decompensated cirrhosis, and within this group, 51% experienced hepatic encephalopathy.¹³ These figures underscore the significant burden of hepatic encephalopathy in patients with cirrhosis.

Chronic liver disease often progresses subtly, with gradual symptoms that may cause patients to delay seeking medical attention until complications arise. This delay can lead to underestimation of the true prevalence of hepatic encephalopathy. A study utilizing a commercial medical claims database estimated the prevalence of hepatic encephalopathy in the United States in 2018 at 202,000 cases.¹⁴ However, it is important to note that this estimate may not fully capture cases of minimal hepatic encephalopathy, which can affect up to 80% of patients with cirrhosis. Minimal hepatic encephalopathy is characterized by subtle cognitive changes that often require specialized testing for detection and may not be evident in routine clinical assessments.⁵ Therefore, the actual prevalence of hepatic encephalopathy may be even higher than reported figures suggest, highlighting the need for increased awareness and improved hepatic encephalopathy diagnosis strategies, particularly for its milder forms.

Pathophysiology of Hepatic Encephalopathy

The neuropathology of hepatic encephalopathy was first described in 1949; however, the precise mechanisms and causes remain incompletely understood.¹ A central element in the pathogenesis of hepatic encephalopathy is the elevated serum ammonia levels. Ammonia is produced in the gastrointestinal tract as colonic bacteria and mucosal enzymes break down dietary proteins. Under normal physiological conditions, this ammonia is absorbed into the portal circulation and transported to the liver, where it is efficiently converted into urea through the urea cycle. However, in patients with hepatic failure or portosystemic shunting, this detoxification process is compromised. Ammonia can bypass the liver and accumulate in the systemic circulation, leading to hyperammonemia. This buildup of ammonia is neurotoxic, disrupting neuronal function and contributing significantly to the development of encephalopathy. Ammonia is recognized as one of several neurotoxic substances that impair excitatory neurotransmission.¹⁵

Pathophysiology in Chronic Liver Failure or Cirrhosis

In individuals with chronic liver failure or cirrhosis, the chronic elevation of ammonia levels has multiple detrimental effects on the brain. Hyperammonemia leads to astrocyte swelling, oxidative stress, and neurotransmitter imbalances, all of which contribute to the clinical manifestations of hepatic encephalopathy. Furthermore, systemic inflammation and alterations in the blood-brain barrier are recognized as significant contributing factors. Changes in the gut microbiome also play a crucial role in ammonia production and the development of hepatic encephalopathy. In patients with long-standing cirrhosis, manganese toxicity represents another potential contributor. This can be detected using magnetic resonance imaging (MRI), particularly T1-weighted imaging, which may reveal abnormalities in the globus pallidus.¹⁶ Besides ammonia and manganese, other substances and factors have been implicated in the pathogenesis of hepatic encephalopathy, including mercaptans, short-chain fatty acids, reduced glutamatergic synaptic function, lactate, and dopamine metabolites.¹⁷ A comprehensive understanding of these multiple pathways is crucial for effective hepatic encephalopathy diagnosis and targeted therapeutic interventions.

Pathophysiology in Acute Liver Failure Without Preexisting Liver Disease

Hepatic encephalopathy secondary to acute liver failure exhibits distinct pathophysiological features, primarily due to the rapid development of brain swelling and the relatively rapid clinical deterioration. This section highlights key aspects of hepatic encephalopathy in the context of acute liver failure.

Ammonia’s ability to cross the blood-brain barrier and enter the brain parenchyma is critical. Within the brain, ammonia is metabolized by astrocytes, where it is converted, along with glutamate, into glutamine by the enzyme astrocytic glutamine synthetase. Glutamine acts as an osmolyte, increasing cerebral volume. This osmotic effect leads to brain edema and intracranial hypertension, significantly elevating the risk of brain herniation.¹⁸

Serum ammonia levels are directly related to the severity of hepatic encephalopathy, particularly in acute liver failure. While this correlation is not strictly linear or exponential, it is more pronounced in patients with fulminant hepatic failure. In these cases, the risk of cerebral edema increases substantially when arterial ammonia levels exceed 200 μmol/L (340 μg/dL).¹ Therefore, monitoring ammonia levels is an important component in the hepatic encephalopathy diagnosis and management in acute liver failure.

Hepatic Encephalopathy in Acute Liver Failure: Etiology

Acute liver failure is defined by severe acute liver injury accompanied by impaired synthetic function, indicated by an international normalized ratio (INR) of ≥1.5, and altered mental status. Critically, this condition typically occurs in patients without preexisting liver disease or cirrhosis.¹⁹

Acute liver failure can arise from various causes, including:

• Acetaminophen (paracetamol) toxicity
• Viral hepatitis
• Autoimmune hepatitis
• Ischemic hepatopathy
• Veno-occlusive disease
• Acute fatty liver of pregnancy
• Toxin exposure, including mushroom poisoning
• Sepsis

Understanding these diverse etiologies is essential for prompt hepatic encephalopathy diagnosis and initiating appropriate treatment strategies in patients with acute liver failure.

Evaluation and Management of Hepatic Encephalopathy Secondary to Acute Liver Failure

The classification of hepatic encephalopathy stages remains consistent for both acute liver failure and cirrhosis, using established grading systems like the West Haven criteria. In patients with acute liver failure and hepatic encephalopathy, cerebral edema is relatively uncommon in those with West Haven grade 1 or 2 encephalopathy. However, its incidence rises sharply with increasing encephalopathy grade, observed in approximately 25% to 35% of patients with grade 3 encephalopathy and about 75% of those with grade 4 encephalopathy.²⁰, ²¹

Increased intracranial pressure (ICP) due to cerebral edema can lead to critical manifestations, including systemic hypertension, bradycardia, and respiratory depression, collectively known as Cushing triad. Other signs of elevated ICP include seizures and abnormal brainstem reflexes. The optimal management of increased intracranial pressure in acute liver failure or fulminant hepatic failure remains a complex clinical challenge.

Potential treatment strategies to manage increased ICP in this setting include:

• Elevating the head end of the bed by 30 degrees to promote venous drainage.
• Cautious administration of short-term sedatives in ventilated patients to prevent patient-ventilator dyssynchrony, while carefully monitoring neurological status.
• Administering boluses of mannitol or hypertonic saline to reduce cerebral edema by osmotic mechanisms.

These interventions aim to mitigate the life-threatening consequences of cerebral edema in acute liver failure-associated hepatic encephalopathy, emphasizing the critical need for rapid hepatic encephalopathy diagnosis and intensive management.

Histopathology of Hepatic Encephalopathy

Histopathological examinations of brain tissue in patients with cirrhosis reveal significant morphological changes primarily affecting astrocytes and microglia.²² These alterations in astrocytes are commonly described as “Alzheimer type II astrocytosis” and are consistently observed in brain tissue sections from individuals who died with grade 4 hepatic encephalopathy. Microscopic analysis shows that hyperammonemia can cause astrocytes to enlarge and appear pale due to a reduction in chromatin content.

It is important to note that these histopathological changes typically develop after prolonged exposure to hyperammonemia and are not commonly seen in cases of fulminant hepatic failure, where the disease progression is too rapid for these chronic changes to manifest. As the most prominent neuropathological changes in individuals with cirrhosis and hepatic encephalopathy involve glial cells rather than neurons, this condition has been characterized as a “primary gliopathy.”²² This distinction is relevant for understanding the underlying cellular mechanisms of hepatic encephalopathy and may have implications for future therapeutic strategies beyond current ammonia-lowering approaches. However, histopathology is not a primary tool for hepatic encephalopathy diagnosis in clinical practice but rather a research tool for understanding the disease process.

History and Physical Examination in Hepatic Encephalopathy Diagnosis

The hepatic encephalopathy diagnosis process begins with confirming the presence of liver disease, typically through abnormal liver function tests, radiologic imaging, or liver biopsy. Alternatively, the identification of a portosystemic shunt can also point towards hepatic encephalopathy. Crucially, it is essential to rule out other potential causes that can mimic hepatic encephalopathy, such as intracranial lesions, masses, stroke, seizure activity, post-seizure encephalopathy, intracranial infections, or toxic encephalopathy from other etiologies. A detailed history and physical examination are paramount in this differential diagnosis.

History Taking

Obtaining a comprehensive patient history is critical for identifying the likely causes of liver failure and guiding appropriate diagnostic and therapeutic interventions. If the patient is unable to communicate effectively due to altered mental status, it is essential to interview close family members, caregivers, or friends who can provide relevant information.

Key areas to explore when gathering a patient’s medical history include:

• Symptoms related to liver failure and its complications: Inquire about jaundice, pruritus, gastrointestinal bleeding, coagulopathy, increased abdominal girth (ascites), renal failure, and changes in mental status.
• Alterations in sleep patterns and cognitive function: Assess for disruptions in sleep-wake cycles, decreased attention span, and impaired short-term memory, and how these changes impact daily activities.
• History of exposure to hepatotoxins: Investigate exposure to alcohol, medications (prescription and over-the-counter), herbal supplements, mushrooms, organic solvents, or phosphorus-containing substances (e.g., those found in fireworks).
• Risk factors for viral hepatitis: Explore travel history, blood transfusions, sexual contacts, and occupational risks.
• Family history of liver disease: Inquire about family history of liver disorders, including Wilson disease or alpha-1 antitrypsin deficiency.
• Potential precipitating factors for encephalopathy: Assess for conditions or events that could trigger hepatic encephalopathy, such as constipation, infection, sedative use, gastrointestinal bleeding, or conditions leading to hypovolemia (e.g., diarrhea or vomiting).

A thorough medical history is indispensable for accurate hepatic encephalopathy diagnosis and for tailoring management strategies to the individual patient.

Physical Examination

The physical examination plays a crucial role in supporting the hepatic encephalopathy diagnosis and assessing the severity and underlying causes.

Signs of Chronic Liver Failure

Patients with hepatic encephalopathy often exhibit physical signs indicative of advanced chronic liver disease, commonly referred to as decompensated cirrhosis. These physical findings may include:

• Muscle wasting and sarcopenia (loss of muscle mass and strength)
• Jaundice (yellowing of the skin and eyes)
• Ascites (abdominal fluid accumulation)
• Palmar erythema (reddening of the palms)
• Edema (swelling, typically in the legs and ankles)
• Spider telangiectasias (small, spider-like blood vessels near the skin’s surface)
• Fetor hepaticus (a distinctive musty or sweet breath odor)

However, it is important to note that in patients with acute fulminant hepatitis without a history of chronic liver disease, some of these findings, such as muscle wasting, spider telangiectasias, and palmar erythema, are typically absent. These physical signs require a longer duration of hepatic dysfunction to develop and are less likely to be present in acute liver failure scenarios. Notably, decreased muscle mass, strength, and function—sarcopenia—is commonly observed in patients with cirrhosis and is associated with an increased risk of hepatic encephalopathy.²³, ²⁴

Neurocognitive and Neuromuscular Signs

Hepatic encephalopathy is characterized by a range of neurocognitive and neuromuscular impairments. The neurocognitive manifestations are variable, with initial signs often including reduced awareness of surroundings and stimuli, accompanied by behaviors such as excessive yawning and episodes of dozing off. Disturbances in the diurnal sleep pattern, such as insomnia or hypersomnia, are common and frequently precede other overt mental status changes or neuromuscular symptoms.²⁵

Neuromuscular manifestations of hepatic encephalopathy include a variety of signs, such as bradykinesia (slowness of movement), asterixis (a characteristic flapping tremor of outstretched, dorsiflexed hands), slurred speech, ataxia (lack of coordination), hyperactive deep tendon reflexes, and nystagmus (involuntary eye movements). Asterixis is typically observed during the intermediate stages of hepatic encephalopathy and is a key clinical sign in hepatic encephalopathy diagnosis.

As hepatic encephalopathy progresses, patients may exhibit restless tossing or muscle or limb twitching, which can evolve into multifocal myoclonus. Additional physical signs may include hyperreflexia, a positive Babinski sign (abnormal plantar reflex), or symptoms resembling Parkinsonian features, such as rigidity or tremors. Less frequently, patients may experience loss of reflexes, transient decerebrate posturing (abnormal body positioning indicating severe brain injury), or progression to a comatose state. In some cases, individuals may present with focal neurological deficits, despite negative findings on computed tomography (CT) or MRI of the brain.²⁶ Recognizing these diverse neurological signs is crucial for timely hepatic encephalopathy diagnosis and intervention.

Evaluation and Diagnostic Tests for Hepatic Encephalopathy

The evaluation process for hepatic encephalopathy diagnosis begins with a rapid assessment of the patient’s vital signs and airway to ensure immediate stability. A detailed clinical evaluation, encompassing a thorough history and physical examination as described earlier, is essential for identifying potential precipitating factors. Understanding the patient’s history of liver disease, previous episodes of encephalopathy, and any associated triggers is crucial for accurate diagnosis and effective management. Hepatic encephalopathy remains a diagnosis of exclusion. Neuroimaging is typically indicated in cases where alternative diagnoses are suspected, such as in patients with compensated cirrhosis experiencing their first episode of hepatic encephalopathy or in individuals with alcohol use disorder and relapse, where other neurological conditions need to be ruled out. It is particularly important to differentiate hepatic encephalopathy from conditions like alcohol withdrawal, as both can present with tremors and asterixis. A key differentiating factor is that the tremor in alcohol withdrawal is typically a fine rhythmic movement, whereas asterixis is a coarse, non-rhythmic flapping tremor of the hands, more characteristic of hepatic encephalopathy.

Diagnostic Tests for Hepatic Encephalopathy

Several diagnostic tests are utilized to support the hepatic encephalopathy diagnosis and rule out other conditions.

Initial Investigations

Initial evaluations for hepatic encephalopathy should include arterial blood gas (ABG) analysis, particularly in patients with higher grades of encephalopathy. ABG analysis can help detect electrolyte imbalances, dehydration, or signs of variceal bleeding, which are common precipitating factors. Blood glucose levels should also be assessed promptly, as hypoglycemia can occur in patients with liver dysfunction and compromised nutritional status and can mimic or exacerbate encephalopathic symptoms.

Ammonia Levels

Ammonia levels are generally elevated in both arterial and venous blood in patients with hepatic encephalopathy. However, it’s important to note that the clinical utility of serial ammonia measurements is limited. Assessing the patient’s clinical improvement or deterioration during treatment is often more valuable than relying solely on absolute ammonia levels. Neither elevated arterial nor venous ammonia concentrations are definitively diagnostic for hepatic encephalopathy.²⁷ However, a normal ammonia level has a high negative predictive value, meaning that hepatic encephalopathy is less likely if ammonia levels are normal. For accurate measurement, ammonia levels should be tested within 1 hour of blood collection and stored at cool temperatures. Emerging biomarkers, such as elevated serum 3-nitrotyrosine levels, are being investigated for their potential role in hepatic encephalopathy diagnosis, particularly in milder forms. Research suggests that a cutoff value of 14 nM for 3-nitrotyrosine has a sensitivity of 93% and a specificity of 89% for detecting minimal hepatic encephalopathy.²⁸ However, these biomarkers are not yet routinely used in clinical practice.

Liver Function Tests and Electrolytes

Liver function tests and electrolyte levels are typically abnormal in patients with underlying liver disease and hepatic encephalopathy. Common findings include elevated levels of bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, prothrombin time (PT), and international normalized ratio (INR). Additionally, patients may exhibit electrolyte imbalances such as hyponatremia and hypokalemia, which are known precipitating factors for hepatic encephalopathy. These laboratory tests provide supportive evidence for hepatic encephalopathy diagnosis and help assess the severity of liver dysfunction.

Additional Tests

Additional tests for hepatic encephalopathy diagnosis may include a complete blood count (CBC), kidney function tests (as kidney injury is a common precipitant), and thyroid-stimulating hormone (TSH) levels to rule out thyroid disorders that can mimic encephalopathy. When sepsis is suspected as a precipitating trigger, investigations for infection, such as blood cultures, procalcitonin, and C-reactive protein (CRP), are essential. These tests also help differentiate hepatic encephalopathy from septic encephalopathy in relevant clinical scenarios.

Psychometric Tests

Psychometric tests have been developed to assess the degree of cognitive impairment in individuals with minimal hepatic encephalopathy, a milder form that may not be evident on routine clinical examination.²⁹, ³⁰, ³¹ These tests have demonstrated greater sensitivity than electroencephalograms (EEG) in detecting subtle cognitive deficits associated with minimal hepatic encephalopathy.²⁹ However, many psychometric tests are complex, time-consuming, and not widely used in routine clinical practice. Critical Flicker Frequency (CFF), which measures visual discrimination, has proven valuable for detecting minimal hepatic encephalopathy in some settings. The Number Connection Test (NCT), also known as the Reitan Test or Trail Making Test Part A, is one of the most commonly used psychometric assessments in clinical practice for hepatic encephalopathy diagnosis and monitoring.³⁰, ³², ³³ The NCT is favored for its ease of administration and interpretation. In the NCT, patients are required to connect numbers in sequential order within a set time. A simplified interpretation is that patients without hepatic encephalopathy typically complete the test in a duration equal to or less than their age in years. For example, a patient aged 50 or older should ideally complete the test in 50 seconds or less. However, normative data and age-adjusted cutoffs should be used for more precise interpretation.

Electroencephalogram (EEG)

Electroencephalogram (EEG) activity in patients with hepatic encephalopathy can reveal non-specific changes such as generalized slowing, high-amplitude slow waves, and triphasic waves. However, these findings are not specific to hepatic encephalopathy and can be seen in other metabolic encephalopathies. An EEG can be helpful during the initial evaluation to rule out seizure activity as a cause of altered mental status, particularly non-convulsive seizures. While not a primary tool for hepatic encephalopathy diagnosis, EEG can provide supportive information in certain clinical contexts.

Radiologic Imaging

Radiologic imaging, such as CT or MRI of the brain, is primarily used in hepatic encephalopathy diagnosis to rule out alternative causes of encephalopathy, including intracranial lesions, masses, or hemorrhage. In some cases, a CT scan during hepatic encephalopathy may show cerebral edema, particularly in acute liver failure and certain cases of post-TIPS hepatic encephalopathy. Although MRI is considered superior to CT for detecting brain edema in liver failure, it is not a routine diagnostic method for hepatic encephalopathy itself. In specific instances, changes have been observed on T1-weighted MRI images, which may reveal a high signal intensity in the basal ganglia, particularly the globus pallidus, in patients with hepatic encephalopathy. This finding has been attributed to manganese accumulation in the brain.³⁴ However, these changes are neither highly sensitive nor specific indicators for hepatic encephalopathy diagnosis.³⁵, ³⁶ Contrast-enhanced CT of the abdomen can be useful for evaluating portosystemic shunts, providing insight into their presence and helping to guide therapeutic interventions, such as shunt embolization or reduction.

Grading of Hepatic Encephalopathy

Following hepatic encephalopathy diagnosis, it is crucial to grade its severity to guide management and prognostication. Traditionally, the West Haven system has been widely used to assess the severity of hepatic encephalopathy, grading it from 0 to 4 based on clinical features. However, the milder stages, particularly grade 0 (minimal hepatic encephalopathy) and grade 1 (subtle confusion or mood changes), can pose diagnostic challenges due to their subtle nature. To address this, the concepts of covert and overt hepatic encephalopathy were introduced. Covert hepatic encephalopathy includes both minimal hepatic encephalopathy and West Haven grade 1, and is typically detectable only through specialized tests like psychometric assessments. Overt hepatic encephalopathy refers to more clinically noticeable symptoms, starting from West Haven grade 2 onward. Additionally, hepatic encephalopathy is classified by its clinical course into episodic, recurrent, and persistent forms, which has implications for long-term management strategies.

Treatment and Management of Hepatic Encephalopathy

The management of hepatic encephalopathy is multifaceted and generally involves supportive care combined with ammonia-lowering therapies. Supportive care is a critical component of treatment, addressing essential needs such as maintaining adequate nutrition, preventing dehydration and electrolyte imbalances, and ensuring a safe environment for the patient. Disaccharides like lactulose and lactitol, and antibiotics like rifaximin, are key pharmacological agents in ammonia-lowering therapy.

Nutritional Support

Contrary to previous misconceptions, patients with hepatic encephalopathy should not have their protein intake restricted. Instead, they require adequate nutritional support with an appropriate energy intake of approximately 35 to 40 kcal/kg/d. The dietary plan should aim to maintain protein intake at around 1.2 to 1.5 gm/kg/d to prevent malnutrition and muscle wasting. It is advisable to encourage the consumption of small, frequent meals throughout the day to prevent prolonged fasting, which can potentially increase ammonia production. For patients who experience worsening symptoms with standard protein intake, vegetable protein sources may be considered as an alternative, as they are thought to be associated with lower ammonia production compared to animal proteins. Additionally, supplementation with branched-chain amino acids (BCAAs) added to a low-protein diet may be considered for individuals who exhibit protein intolerance. This approach may be particularly beneficial for patients undergoing procedures like TIPS or surgical portosystemic shunts who are also experiencing hepatic encephalopathy.

Hydration and Electrolyte Correction

Supportive care also includes meticulous attention to hydration status and correction of electrolyte imbalances. This involves ensuring proper hydration with adequate oral fluids and, when necessary, administering intravenous fluids to prevent dehydration. Any identified electrolyte abnormalities, such as hyponatremia or hypokalemia, should be promptly corrected by replenishing essential electrolytes as needed. Addressing these factors is crucial as dehydration and electrolyte imbalances are known precipitating factors for hepatic encephalopathy.

Safe Environment

Creating a safe environment is paramount for patients with overt hepatic encephalopathy symptoms, as they may experience agitation, confusion, and impaired coordination, posing a risk to themselves and their caregivers. While managing agitation, it is crucial to recognize that sedative medications, particularly benzodiazepines, can potentially exacerbate encephalopathy and hinder recovery. Therefore, the use of sedatives should be carefully considered and minimized if possible. In some situations, temporary physical restraint may be necessary to ensure patient safety until the agitation resolves, but this should be used judiciously and in conjunction with efforts to identify and manage underlying causes of agitation.

Treatment of Precipitating Factors

Prompt identification and treatment of precipitating factors are essential for the effective management of hepatic encephalopathy. These triggers can include constipation, infections (such as spontaneous bacterial peritonitis or urinary tract infections), electrolyte and metabolic imbalances (e.g., hypokalemia or hypoglycemia), hypovolemia, and the use of benzodiazepines or other sedatives. Timely and effective intervention to correct these precipitating factors is a cornerstone of hepatic encephalopathy management.

Ammonia-Lowering Medications

In most cases of hepatic encephalopathy, ammonia levels are elevated, although this is not universally true. Regardless of the measured ammonia levels, therapeutic strategies aimed at reducing ammonia levels are typically initiated once a hepatic encephalopathy diagnosis is confirmed and precipitating factors are addressed. However, it is important to emphasize that elevated serum ammonia levels alone, without corresponding clinical signs of hepatic encephalopathy, do not automatically warrant ammonia-lowering therapy. The decision to initiate treatment should be based on a comprehensive clinical assessment and the presence of encephalopathy symptoms, rather than solely on ammonia levels.

Commonly used medications for managing hepatic encephalopathy include disaccharides such as lactulose and lactitol, and the antibiotic rifaximin.

Lactulose and Lactitol

Lactulose and lactitol are synthetic disaccharides that are poorly absorbed in the small intestine. They reach the colon where they are metabolized by colonic bacteria, leading to acidification of the colonic contents. This acidification promotes the conversion of ammonia (NH3) to ammonium (NH4+), which is less readily absorbed and is excreted in the stool. Lactulose and lactitol also act as cathartics, promoting bowel movements and further facilitating the removal of nitrogenous waste products from the body. Lactulose is typically administered orally or rectally, with the dosage adjusted to achieve 2 to 3 soft bowel movements per day. Common side effects include abdominal bloating, gas, and diarrhea.

Rifaximin

Rifaximin is a non-absorbable antibiotic that acts primarily within the gastrointestinal tract. It is believed to reduce ammonia production by targeting and reducing the population of ammonia-producing bacteria in the colon. Rifaximin works by binding to bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and consequently bacterial growth. Rifaximin is often considered for patients who do not adequately respond to or are intolerant of lactulose or lactitol. It can also be used in combination with lactulose for enhanced ammonia control. Rifaximin is typically prescribed at a dosage of 550 mg orally twice daily or 400 mg orally 3 times daily. Due to its minimal systemic absorption, rifaximin has a favorable safety profile, with common side effects being mild gastrointestinal symptoms.

Closure of Portosystemic Shunts

In patients with refractory hepatic encephalopathy caused by large portosystemic shunts, procedures aimed at shunt closure may be considered. Balloon-occluded retrograde transvenous obliteration (BRTO) or plug-assisted retrograde transvenous obliteration (PARTO) are interventional radiology techniques that can effectively close these shunts. By closing the shunts, these procedures aim to restore more normal portal circulation to the liver, reduce systemic shunting, and consequently decrease ammonia accumulation in the systemic circulation. These procedures are typically reserved for carefully selected patients with recurrent or persistent hepatic encephalopathy despite medical management.

Extracorporeal Albumin Dialysis

Extracorporeal albumin dialysis, often referred to as liver dialysis, is a more advanced therapeutic modality that may be considered for severe hepatic encephalopathy, particularly in acute-on-chronic liver failure (ACLF). Techniques like DIALIVE and other similar systems are available. These systems are designed to remove albumin-bound toxins, including ammonia, bilirubin, cytokines, and bile acids, from the circulation. The rationale is that by removing these toxins, extracorporeal albumin dialysis can reduce the severity of hepatic encephalopathy and support liver function recovery. While studies have shown that these therapies can improve encephalopathy symptoms and reduce ammonia levels in patients with ACLF, definitive evidence of long-term survival benefit is still evolving, and the impact on overall mortality remains uncertain.⁴¹, ⁴² Extracorporeal albumin dialysis is often resource-intensive and may not be available at all medical centers, limiting its widespread use in hepatic encephalopathy diagnosis and management.

Liver Transplantation

Liver transplantation is often considered the definitive treatment for patients with cirrhosis and recurrent or severe hepatic encephalopathy. It is typically considered for patients with cirrhosis who develop major complications, such as ascites, hepatic encephalopathy, or variceal bleeding, or when their Model for End-Stage Liver Disease (MELD) score exceeds 15, indicating severe liver dysfunction.⁴³ A single episode of overt hepatic encephalopathy significantly increases mortality risk, independent of other organ failures, and referral to a liver transplantation center for evaluation should be considered in these cases.⁴⁴ In patients who are candidates for and undergo successful liver transplantation, cognitive impairment associated with hepatic encephalopathy often reverses within 5 years after transplantation.⁴⁵ This highlights the potential for substantial improvement in cognitive function and overall quality of life following successful liver transplantation, making it a crucial consideration in the long-term management of hepatic encephalopathy.

Chronic Management and Prevention

For individuals at risk of recurrent hepatic encephalopathy, identifying and managing potential precipitating factors is crucial for long-term management and prevention. When precipitating factors cannot be identified or effectively controlled, ongoing prophylactic therapy with disaccharides such as lactulose or lactitol, often in combination with rifaximin, can be beneficial in reducing the risk of recurrent episodes.

Prevention of Hepatic Encephalopathy

Lactulose is recommended for patients with cirrhosis after their first episode of covert hepatic encephalopathy to prevent progression to overt hepatic encephalopathy and reduce the risk of further episodes. If a patient is already on lactulose and experiences another episode of hepatic encephalopathy, the addition of rifaximin may be considered to enhance ammonia control and prevent recurrence. Management of sarcopenia, which is associated with increased risk of hepatic encephalopathy, requires a comprehensive approach including proper nutritional support and a structured exercise plan incorporating both resistance and aerobic exercises. While BCAAs show promise in addressing sarcopenia, further research is needed to definitively confirm their efficacy in this context. Preventative strategies, combined with prompt hepatic encephalopathy diagnosis and management of acute episodes, are essential for improving long-term outcomes in patients with liver disease.

Differential Diagnosis of Hepatic Encephalopathy

The hepatic encephalopathy diagnosis process requires careful differentiation from a range of other conditions that can present with similar neurological symptoms. The differential diagnoses of hepatic encephalopathy include the following categories:

• Metabolic causes: Hypoglycemia, hypoxia, hypercapnia, hyponatremia, hypernatremia, thyroid disorders, and alcohol withdrawal.
• Intracranial lesions: Subdural hematoma, epidural hematoma, intracranial hemorrhage (intracerebral or subarachnoid), brain tumor (primary or metastatic), stroke (ischemic or hemorrhagic), and brain abscess.
• Other primary central nervous system processes: Meningitis (bacterial, viral, or fungal), encephalitis, Wernicke encephalopathy (thiamine deficiency encephalopathy), and post-seizure encephalopathy.
• Sepsis and septic encephalopathy: Systemic infection leading to altered mental status.
• Uremic encephalopathy: Encephalopathy associated with kidney failure and uremia.
• Drug-related effects: Antipsychotics, sedatives, antidepressants, anticholinergics, and medications like valproate can cause altered mental status or, in some cases, hyperammonemia without liver dysfunction.

A thorough clinical evaluation, appropriate laboratory investigations, and neuroimaging when indicated are essential to systematically rule out these alternative diagnoses and confirm hepatic encephalopathy diagnosis.

Pertinent Studies and Ongoing Trials in Hepatic Encephalopathy Treatment

Research continues to explore and refine treatment strategies for hepatic encephalopathy. Several treatment modalities have been investigated, with some showing promising results in improving patient outcomes.

Branched-Chain Amino Acid (BCAA) Infusions

Numerous randomized controlled trials have evaluated the use of parenteral nutrition with modified amino acid solutions that are enriched with BCAAs and have a lower concentration of aromatic amino acids. Patients with cirrhosis often exhibit a disproportionate depletion of BCAAs compared to aromatic amino acids, which is hypothesized to contribute to neurotransmitter imbalances in hepatic encephalopathy. However, the evidence regarding the effect of BCAA infusions on mortality remains conflicting, and many studies conducted to date have been limited by small sample sizes and relatively short follow-up periods. Consequently, routine BCAA infusions are not currently recommended as a standard treatment for hepatic encephalopathy in clinical guidelines.⁴⁶

Oral BCAA Supplements

Several clinical trials have investigated the effects of oral BCAA supplements in patients with hepatic encephalopathy. Some studies have suggested potential beneficial effects of oral BCAAs on improving symptoms of hepatic encephalopathy and nutritional status, although clear mortality benefits have not been consistently demonstrated. Patients with hyperammonemia and liver disease are often deficient in amino acids, and BCAAs play a crucial role as building blocks for neurotransmitter synthesis and muscle protein synthesis. This may explain their potential, albeit limited, effectiveness in managing certain aspects of hepatic encephalopathy.⁴⁰, ⁴⁷, ⁴⁸ Current guidelines generally do not recommend routine oral BCAA supplementation for hepatic encephalopathy.

Polyethylene Glycol (PEG)

Polyethylene glycol (PEG) solution, a commonly used cathartic agent for bowel preparation and constipation treatment, has been explored as a potential therapy for hepatic encephalopathy. PEG acts by osmotically drawing water into the colon, promoting bowel movements and enhancing the excretion of ammonia through the stool. Several studies have compared PEG to lactulose in the treatment of overt hepatic encephalopathy. Some of these studies have reported that patients treated with PEG experienced more significant improvements in their hepatic encephalopathy scoring algorithm (HESA) scores compared to those receiving lactulose. These findings suggest that PEG could be a viable alternative or adjunctive option for managing hepatic encephalopathy, particularly for patients who may not tolerate lactulose or require more aggressive bowel cleansing.⁴⁹, ⁵⁰

Sodium Benzoate

Sodium benzoate is a medication that reduces ammonia levels through a chemical reaction with glycine in the body. This reaction forms hippurate, which is then excreted by the kidneys, effectively removing nitrogenous waste and reducing ammonia burden. A clinical trial evaluating sodium benzoate in the treatment of acute hepatic encephalopathy demonstrated that sodium benzoate improved hepatic encephalopathy symptoms to a similar extent as lactulose.⁵¹ While these results are promising, further research is needed to more definitively establish the role of sodium benzoate as a first-line or second-line therapy for hepatic encephalopathy and to clarify its optimal place in treatment algorithms.

Probiotics

Probiotic therapy, involving the administration of beneficial bacteria, has been investigated for its potential to reduce blood ammonia concentrations in patients with hepatic encephalopathy. Probiotics are thought to work by modulating the gut microbiome, promoting the colonization of acid-resistant, non-urease–producing bacteria, and reducing the population of urease-producing bacteria that contribute to ammonia generation in the gut. Lactobacillus and Bifidobacterium species are among the probiotics that have been studied in the context of hepatic encephalopathy. While probiotics are often used empirically in clinical practice due to their perceived safety and potential benefits in gut health, the rigorous scientific data supporting their effectiveness in treating hepatic encephalopathy is still limited, and current guidelines do not strongly recommend their routine use.²⁵, ⁵²

Flumazenil

Flumazenil is a benzodiazepine receptor antagonist that is primarily used to reverse the sedative effects of benzodiazepines. It has been explored as a potential treatment for hepatic encephalopathy based on the hypothesis that endogenous benzodiazepine-like substances may contribute to the pathogenesis of hepatic encephalopathy. Flumazenil may provide temporary improvement in mental status in some patients with hepatic encephalopathy. However, a large meta-analysis evaluating flumazenil in hepatic encephalopathy found that it did not significantly affect all-cause mortality. While some evidence suggests potential short-term benefits in select patients, flumazenil is not currently a recommended or widely used treatment for hepatic encephalopathy.⁵³

Zinc Supplementation

Zinc deficiency is known to be prevalent in patients with cirrhosis and hepatic encephalopathy. Zinc plays a role in the urea cycle, and zinc deficiency may impair ammonia detoxification. Studies investigating zinc supplementation in patients with hepatic encephalopathy have yielded inconsistent results. Some studies have suggested potential benefits of zinc supplementation in improving mental status or reducing ammonia levels, while others have not shown significant effects. Due to the inconsistent evidence, routine recommendations for zinc supplementation in all patients with cirrhosis and hepatic encephalopathy have not been established. However, zinc supplementation may be considered in patients with documented zinc deficiency, particularly if they have recurrent hepatic encephalopathy or are refractory to standard therapies.

Other investigational agents and approaches under exploration for hepatic encephalopathy treatment include fecal microbiota transplantation (FMT), L-carnitine, serotonin antagonists, and opioid antagonists. Further well-designed clinical trials are necessary to comprehensively assess the effectiveness and safety of these emerging therapies and to determine their potential role in the future management of hepatic encephalopathy. Continued research efforts are crucial for advancing the treatment of this challenging condition and improving outcomes for affected patients.

Staging and Classification of Hepatic Encephalopathy

Accurate staging and classification are essential components of hepatic encephalopathy diagnosis and management, guiding treatment strategies and providing prognostic information. Hepatic encephalopathy can be staged using the West Haven criteria, a widely adopted semi-quantitative grading system that assesses mental state based on the degree of dependence on therapy and impairments in autonomy, behavior, consciousness, and intellectual function. Alternatively, the World Health Congress of Gastroenterology criteria offer a classification system based on the underlying etiology and associated clinical conditions of hepatic encephalopathy.⁵⁵

West Haven Criteria for Hepatic Encephalopathy

The West Haven criteria provide a structured framework for assessing the severity of hepatic encephalopathy, ranging from subtle cognitive changes to profound coma. The West Haven grades are as follows:

• Grade 1 (Minimal Hepatic Encephalopathy or MHE):
  • Trivial lack of awareness.
  • Euphoria or anxiety.
  • Shortened attention span and impaired ability to perform simple calculations (addition or subtraction).
• Grade 2 (Mild Hepatic Encephalopathy):
  • Lethargy or apathy.
  • Minimal disorientation to time or place.
  • Subtle personality changes.
  • Inappropriate behavior.
• Grade 3 (Moderate Hepatic Encephalopathy):
  • Somnolence to semi-stupor, but responsive to verbal stimuli.
  • Confusion.
  • Gross disorientation (to time and place).
• Grade 4 (Severe Hepatic Encephalopathy):
  • Coma (unresponsive to verbal or painful stimuli).

World Health Congress of Gastroenterology Criteria for Hepatic Encephalopathy

The World Health Congress of Gastroenterology criteria classify hepatic encephalopathy into distinct types based on its underlying etiology, providing a more etiologically-focused approach to classification and management:

• Type A (Acute): Hepatic encephalopathy associated with acute liver failure. This type is often characterized by rapid onset and is frequently accompanied by cerebral edema.
• Type B (Bypass): Hepatic encephalopathy caused by portal-systemic shunting in the absence of significant intrinsic liver disease. This type results from diversion of portal blood flow away from the liver, leading to systemic exposure to gut-derived neurotoxins.
• Type C (Cirrhosis): Hepatic encephalopathy occurring in patients with cirrhosis. Type C is further subdivided based on its clinical course:
  • Episodic Hepatic Encephalopathy: Episodes of overt hepatic encephalopathy that are often precipitated by identifiable triggers.
  • Recurrent Hepatic Encephalopathy: Repeated episodes of overt hepatic encephalopathy occurring within a defined time period.
  • Persistent Hepatic Encephalopathy: A chronic, ongoing state of overt hepatic encephalopathy.
  • Minimal Hepatic Encephalopathy (MHE) or Covert Hepatic Encephalopathy: This is also classified under Type C, representing the milder, subclinical form of hepatic encephalopathy detectable only by neuropsychological testing.

Minimal Hepatic Encephalopathy (MHE)

Minimal hepatic encephalopathy (MHE), also referred to as covert hepatic encephalopathy, is a subtle form of hepatic encephalopathy that is not characterized by overt clinical signs of cognitive dysfunction. Instead, MHE manifests as subtle cognitive deficits that are detectable primarily through specialized neuropsychological testing.⁵ Despite its subtle nature, MHE has significant clinical implications. It has been shown to impair overall quality of life, reduce work productivity and functional capacity, and increase the risk of motor vehicle accidents due to impaired attention, psychomotor speed, and decision-making. Hepatic encephalopathy diagnosis in MHE relies on psychometric testing, including tests like the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the PSE-Syndrome test. These tests incorporate a range of neuropsychological assessments that measure multiple cognitive domains, providing a more comprehensive and reliable evaluation than tests focused on individual cognitive functions alone.

Treatment with rifaximin or lactulose has demonstrated improvements in quality of life and cognitive function in patients with MHE. Rifaximin has also been shown to improve driving performance in simulated driving experiments in patients with MHE. Additionally, the combination of rifaximin and lactulose has proven effective in preventing the recurrence of episodic overt hepatic encephalopathy in patients with cirrhosis, highlighting the importance of early hepatic encephalopathy diagnosis and intervention even in its milder forms.

General Classification: Covert and Overt Hepatic Encephalopathy

Hepatic encephalopathy is broadly categorized into two main types based on clinical presentation: covert and overt. While precise prevalence statistics for each form are not available, these categories represent a spectrum of disease severity. Covert hepatic encephalopathy encompasses minimal hepatic encephalopathy (MHE) and West Haven grade 1, representing the milder, less clinically apparent end of the spectrum. Overt hepatic encephalopathy encompasses West Haven grades 2 through 4, characterized by more clinically obvious and significant neurological and cognitive dysfunction.⁵⁶ This distinction is clinically relevant as covert and overt hepatic encephalopathy may require different diagnostic and management approaches.

Prognosis of Hepatic Encephalopathy

The prognosis for patients who develop hepatic encephalopathy, particularly in the context of chronic liver disease, is generally guarded and associated with significant morbidity and mortality. Patients with chronic liver disease who develop hepatic encephalopathy are at a high risk of recurrence of encephalopathic episodes. Even after successful treatment of an acute episode, some neurological deficits and cognitive impairments may persist, despite an apparent return to baseline mental status. The severity of these residual impairments tends to be greater in individuals who have experienced multiple overt episodes of hepatic encephalopathy. Additionally, hepatic encephalopathy is a strong indicator of poor prognosis in individuals with underlying liver failure.⁵⁷ Studies have consistently shown reduced survival rates in patients with hepatic encephalopathy compared to those without. For instance, a study involving hospitalized patients with hepatic encephalopathy reported a survival probability of only 44% at 12 months and 35% at 24 months.⁵⁸ These figures underscore the serious nature of hepatic encephalopathy and the importance of early hepatic encephalopathy diagnosis, effective management, and consideration of liver transplantation in eligible patients to improve prognosis.

Complications of Hepatic Encephalopathy

Hepatic encephalopathy is associated with a range of complications that can significantly impact patient outcomes and quality of life. These complications include:

• Agitation: Patients with hepatic encephalopathy, particularly in overt stages, may experience agitation, restlessness, and irritability. This agitation can pose a potential risk of harm to both patients and their caregivers, necessitating careful management and a safe environment.
• Seizures: Hepatic encephalopathy can lower the seizure threshold, increasing the risk of seizures, particularly in more severe grades of encephalopathy. Seizures can further complicate management and worsen neurological outcomes.
• Residual cognitive impairment: Even in patients who show clinical improvement in mental status after treatment of hepatic encephalopathy, residual cognitive impairment may persist. This can manifest as subtle deficits in attention, memory, executive function, and psychomotor speed, impacting daily functioning and quality of life.
• Decreased likelihood of survival: Recurrent episodes of overt hepatic encephalopathy are associated with a significantly decreased likelihood of survival within 12 to 24 months. Hepatic encephalopathy is a marker of advanced liver disease and poor overall prognosis.
• Cerebral edema, seizures, and brain herniation in acute fulminant hepatic failure: In the context of acute fulminant hepatic failure, hepatic encephalopathy can progress rapidly and severely. Cerebral edema is a major life-threatening complication, leading to increased intracranial pressure, which can result in seizures, brain herniation, and death.

Recognizing and proactively managing these potential complications is essential for optimizing patient care and improving outcomes in hepatic encephalopathy. Prompt hepatic encephalopathy diagnosis and comprehensive management strategies are crucial in mitigating these risks.

Postoperative and Rehabilitation Care for Hepatic Encephalopathy

Postoperative hepatic encephalopathy is a recognized complication in patients with cirrhosis undergoing surgical procedures. A study involving patients with cirrhosis who underwent non-hepatic surgery found that 7.2% developed postoperative hepatic encephalopathy.⁵⁹ Postoperative hepatic encephalopathy is associated with adverse outcomes, including increased morbidity and mortality. Therefore, careful preoperative optimization of patients with cirrhosis undergoing surgery is crucial to reduce this risk. Strategies to improve preoperative status include optimizing the patient’s Child-Turcotte-Pugh score, addressing any hemodynamic and metabolic abnormalities, and carefully considering the choice of anesthetic agents. Selecting anesthetics with lower hepatotoxicity may contribute to better outcomes in this patient population.⁵⁹, ⁶⁰

During the postoperative and rehabilitation phases, meticulous monitoring and management are essential to prevent or promptly address potential complications. Key aspects of postoperative and rehabilitation care include:

• Close monitoring for and correction of electrolyte imbalances.
• Prevention and management of constipation.
• Vigilant prevention and prompt treatment of infections.
• Nutritional support: Ensuring adequate caloric intake while avoiding protein restriction, as discussed earlier.
• Avoidance of nephrotoxic and hepatotoxic medications whenever possible.
• Judicious use of sedatives, as they can exacerbate hepatic encephalopathy.

A multidisciplinary approach involving surgeons, hepatologists, anesthesiologists, nurses, and rehabilitation specialists is crucial to optimize postoperative outcomes and facilitate recovery in patients with cirrhosis and hepatic encephalopathy.⁶¹ Early hepatic encephalopathy diagnosis and proactive management in the postoperative setting can significantly improve patient outcomes.

Consultations for Hepatic Encephalopathy Management

Optimal management of hepatic encephalopathy often necessitates consultations with various specialists to address the multifaceted aspects of this condition. Consultations may include:

• Hepatologists: For comprehensive liver disease management and coordination of care.
• Nutritionists: To develop tailored dietary plans, ensuring adequate caloric and protein intake while addressing specific nutritional needs (e.g., 30-35 kcal/kg/d and 1-1.5 g protein/kg/d).
• Physiotherapists: To design customized exercise plans, including isometric and isotonic exercises, to combat sarcopenia and improve functional status.
• Neurologists: To rule out other neurological conditions in the differential diagnosis and manage neurological symptoms associated with hepatic encephalopathy, such as parkinsonism.
• Neuro-intensivists: For higher-grade hepatic encephalopathy cases requiring intensive care unit (ICU) management, particularly in acute liver failure or severe overt encephalopathy.
• Psychiatrists: For management of behavioral symptoms associated with hepatic encephalopathy, such as agitation or personality changes, and to differentiate hepatic encephalopathy from psychiatric conditions or alcohol withdrawal.
• Interventional radiologists: For consideration of TIPS reduction or shunt closure procedures (BRTO or PARTO) in refractory hepatic encephalopathy.
• Liver transplant surgeons: To evaluate patients for liver transplantation candidacy, particularly in cases of recurrent or severe hepatic encephalopathy.

Effective interdisciplinary communication and collaboration among these specialists are essential to provide comprehensive and patient-centered care for individuals with hepatic encephalopathy. Timely hepatic encephalopathy diagnosis and coordinated specialist input are key to optimizing patient management and outcomes.

Deterrence and Patient Education for Hepatic Encephalopathy

Patient education is a critical component in the comprehensive management of hepatic encephalopathy. Patients at risk for hepatic encephalopathy, as well as their caregivers, should be educated about the condition, including its symptoms, potential triggers, chronic management strategies, and when to seek medical assistance. Proactive patient and caregiver education empowers them to play an active role in disease management and prevention. Key points to include during patient education are outlined below.

Patient Education Points

• Recognize early warning signs: Patients should be educated to recognize early warning signs and symptoms of hepatic encephalopathy, such as subtle changes in sleep patterns, new onset confusion, reduced attention span, personality changes, or worsening of existing symptoms.
• Identify and avoid triggers: Patients need to be vigilant about potential triggers that can precipitate hepatic encephalopathy episodes. Education should emphasize avoiding or managing triggers such as infections, constipation, use of sedative medications, gastrointestinal bleeding, and dehydration.
• Avoid hepatotoxins: Patients should be counselled to strictly avoid hepatotoxins, including alcohol consumption, certain herbal medications or supplements that may be harmful to the liver, and unapproved dietary supplements.
• Medication adherence: Patients must understand the importance of adhering to their prescribed medication regimens, particularly lactulose and rifaximin. For example, patients taking lactulose should be instructed that the goal is to achieve 2 to 3 soft bowel movements daily, and they should adjust their dose accordingly and as directed by their healthcare provider.
• Seek prompt medical attention: Patients should be instructed to seek immediate medical attention if they experience worsening symptoms or new concerning symptoms, such as fever, increased abdominal swelling, worsening jaundice, deteriorating mental status, or any signs of infection or gastrointestinal bleeding.

Caregiver Education Points

• Recognize subtle signs: Caregivers play a crucial role in monitoring patients for subtle signs of hepatic encephalopathy, especially in cases of minimal hepatic encephalopathy (MHE) or covert hepatic encephalopathy. Patients themselves may lack insight into their subtle cognitive changes, making caregiver observation essential.
• Safe management of agitation and confusion: Caregivers should be guided on how to safely manage agitation and confusion in patients with hepatic encephalopathy without resorting to potentially harmful sedatives. Strategies for de-escalation, creating a calm environment, and ensuring patient safety should be discussed.
• When to seek urgent medical help: Caregivers should be clearly informed about when to seek urgent medical help for the patient, particularly in cases of rapidly worsening confusion, increased drowsiness, new-onset agitation that is difficult to manage, or any other concerning changes in the patient’s condition.

Driving Restrictions

Patients with a history of overt hepatic encephalopathy or those diagnosed with minimal hepatic encephalopathy (MHE) should be strongly advised to avoid driving. Hepatic encephalopathy, even in its milder forms, can impair cognitive and psychomotor function, significantly increasing the risk of motor vehicle accidents. This recommendation is supported by evidence demonstrating impaired attention, delayed reaction times, and reduced executive function in patients with hepatic encephalopathy. Driving restrictions should be clearly communicated to patients and their families as a crucial safety measure.

Lifestyle and Long-Term Strategies

• Regulated diet and avoid prolonged fasting: Patients should be educated on the importance of maintaining a regulated diet that is rich in protein (as recommended by their healthcare provider) and to avoid prolonged fasting periods. Strategies such as adding a late-night snack may be suggested to help reduce the risk of nocturnal ammonia buildup.
• Routine follow-up: Emphasize the need for routine follow-up appointments with their healthcare providers to monitor liver function, cognitive status, and the effectiveness of hepatic encephalopathy treatments. Regular monitoring allows for timely adjustments to the management plan as needed.
• Adherence to exercise plans: Patients should be encouraged to adhere to prescribed exercise plans, as physical activity can help improve overall health, muscle strength, and potentially cognitive function.

Comprehensive patient and caregiver education, combined with proactive strategies for deterrence and long-term management, are integral to improving outcomes and quality of life for individuals with hepatic encephalopathy. Effective education supports early hepatic encephalopathy diagnosis and empowers patients and caregivers to actively participate in managing this complex condition.

Pearls and Key Issues in Hepatic Encephalopathy

Key facts and essential considerations to keep in mind regarding hepatic encephalopathy include:

• Toxin accumulation: Hepatic encephalopathy primarily results from the accumulation of neurotoxins, with ammonia being a major contributor, which are normally metabolized and detoxified by the liver.
• Liver failure or shunting: Hepatic encephalopathy develops due to liver failure (acute or chronic) or the redirection of blood flow away from the liver, such as in portosystemic shunting, preventing proper hepatic detoxification.
• Ammonia levels are not always elevated: While ammonia is commonly measured and targeted in treatment, elevated ammonia levels are not a prerequisite for hepatic encephalopathy diagnosis. The condition can occur even when ammonia levels are within the normal range, and the correlation between ammonia levels and encephalopathy severity is not always linear. Clinical assessment remains paramount.
• Mild HE is often underrecognized: Mild hepatic encephalopathy (minimal or covert HE) is frequently underrecognized by patients, caregivers, and even healthcare providers due to its insidious onset and subtle, slowly progressive nature. Routine clinical exams may miss these subtle cognitive deficits, highlighting the need for increased awareness and use of psychometric testing in at-risk individuals.
• Acute vs. chronic liver failure differences: Individuals with acute liver failure without pre-existing chronic liver disease present differently and face distinct risks compared to those with chronic liver disease. In acute liver failure, the rapid rise in intracerebral osmolytes, particularly glutamine, can lead to severe cerebral edema, coma, brain herniation, and death, requiring intensive monitoring and management of intracranial pressure.
• Current treatments are palliative: Current treatments for hepatic encephalopathy, such as lactulose, rifaximin, and shunt reduction/closure, are primarily aimed at managing symptoms and reducing ammonia levels. They do not represent a cure for the underlying liver disease. L-ornithine-L-aspartate (LOLA) is also used in some regions. Experimental treatments under investigation include BCAAs, PEG, and sodium benzoate, but their roles are not yet fully established in standard clinical practice.
• Extracorporeal albumin dialysis: Extracorporeal albumin dialysis (liver dialysis) is an emerging option for severe hepatic encephalopathy, but it is often expensive, not universally available, and its impact on long-term survival remains uncertain.
• High mortality rate: Hepatic encephalopathy is associated with a high mortality rate. The 1-year mortality rate for individuals diagnosed with hepatic encephalopathy exceeds 40%, underscoring the seriousness of the condition and the need for close monitoring and aggressive management.
• Liver transplantation is the definitive cure: Liver transplantation remains the only definitive cure for hepatic encephalopathy in patients with underlying liver disease. It should be considered for eligible patients with recurrent or severe hepatic encephalopathy.

These key points emphasize the complexity of hepatic encephalopathy diagnosis and management, highlighting the need for a comprehensive, multidisciplinary approach to improve patient outcomes.

Enhancing Healthcare Team Outcomes in Hepatic Encephalopathy Management

Hepatic encephalopathy is a complex condition with a poor prognosis, with mortality rates exceeding 40% within 12 months of diagnosis. Given this high mortality and the multifaceted nature of the condition, a collaborative, interprofessional healthcare team approach is essential to optimize patient care, improve quality of life, and potentially enhance survival. Upon hepatic encephalopathy diagnosis, prompt referral to a liver transplant center for thorough evaluation of transplantation eligibility is often crucial, as liver transplantation may be the only curative option for many patients. The core healthcare team involved in managing hepatic encephalopathy typically includes internists, gastroenterologists, hepatologists, neurologists, neurointensivists (for severe cases), and radiologists.

Pharmacists play a vital role in medication management for patients with hepatic encephalopathy. They oversee the medications prescribed, ensuring appropriate dosing and monitoring for potential drug interactions or adverse effects. Certain medications can exacerbate hepatic encephalopathy or have prolonged effects due to impaired liver metabolism. Pharmacists can assist in adjusting medication dosages, identifying and avoiding potentially hepatotoxic drugs, and ensuring appropriate ammonia-lowering therapy.

Nursing staff are central to patient care, providing continuous monitoring of patients’ clinical status, administering medications, and educating patients and their families about hepatic encephalopathy, its progression, and potential complications. Nurses are often the first to detect subtle changes in a patient’s mental status, which is critical for early intervention. Many patients with hepatic encephalopathy may have limited insight into their condition and may require assistance with daily activities. In such cases, consulting with social workers, home care nurses, and physical therapists is highly recommended to provide comprehensive support and address patients’ functional and psychosocial needs.

Furthermore, involving a registered dietitian is essential to ensure patients receive adequate and appropriate nutritional support, tailored to their individual needs and preferences. While current treatment modalities can improve symptoms and quality of life in some patients with hepatic encephalopathy, it is important to acknowledge that none of the current medical treatments offer a definitive cure, and liver transplantation is not universally accessible to all patients. Given the significant burden of this disease, a well-coordinated interprofessional approach, emphasizing effective communication and shared decision-making, is strongly recommended to optimize the management of hepatic encephalopathy and improve patient outcomes. Effective teamwork, starting from accurate hepatic encephalopathy diagnosis to ongoing supportive care, is paramount in addressing this challenging condition.

Review Questions

(Note: Review questions from the original article are omitted as per instructions)

References

(Note: References from the original article are included and formatting is maintained)

1.Wijdicks EF. Hepatic Encephalopathy. N Engl J Med. 2016 Oct 27;375(17):1660-1670. [PubMed: 27783916]

2.Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology. 2009 Dec;50(6):2014-21. [PubMed: 19787808]

3.Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dölle W. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci. 1981 Jul;26(7):622-30. [PubMed: 7249898]

4.Ortiz M, Córdoba J, Jacas C, Flavià M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006 Jan;44(1):104-10. [PubMed: 16169117]

5.Sharma P. Minimal hepatic encephalopathy. J Assoc Physicians India. 2009 Nov;57:760-3. [PubMed: 20329443]

6.Fichet J, Mercier E, Genée O, Garot D, Legras A, Dequin PF, Perrotin D. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care. 2009 Sep;24(3):364-70. [PubMed: 19327960]

7.García-Martínez R, Simón-Talero M, Córdoba J. Prognostic assessment in patients with hepatic encephalopathy. Dis Markers. 2011;31(3):171-9. [PMC free article: PMC3826802] [PubMed: 22045403]

8.Saad WE. Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin Intervent Radiol. 2014 Sep;31(3):262-5. [PMC free article: PMC4139430] [PubMed: 25177088]

9.Rössle M, Haag K, Ochs A, Sellinger M, Nöldge G, Perarnau JM, Berger E, Blum U, Gabelmann A, Hauenstein K. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med. 1994 Jan 20;330(3):165-71. [PubMed: 8264738]

10.Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008 Nov;103(11):2738-46. [PubMed: 18775022]

11.Rajesh S, Philips CA, Ahamed R, Abduljaleel JK, Nair DC, Augustine P. Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects. Can J Gastroenterol Hepatol. 2021;2021:8795115. [PMC free article: PMC8376437] [PubMed: 34422711]

12.Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology. 2018 Oct;68(4):1498-1507. [PubMed: 29091289]

13.Orman ES, Roberts A, Ghabril M, Nephew L, Desai AP, Patidar K, Chalasani N. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. JAMA Netw Open. 2019 Jun 05;2(6):e196412. [PMC free article: PMC6604080] [PubMed: 31251379]

14.Potnis A, VanMeter S, Stange J. Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States. Int J Hepatol. 2021;2021:8542179. [PMC free article: PMC8208864] [PubMed: 34211786]

15.Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987 Feb-Apr;6(1-2):1-12. [PubMed: 3306479]

16.Butterworth RF, Spahr L, Fontaine S, Layrargues GP. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis. 1995 Dec;10(4):259-67. [PubMed: 8847990]

17.Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol. 2016 Jun;160:94-7. [PubMed: 26589093]

18.Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S96-S103. [PMC free article: PMC4442857] [PubMed: 26041966]

19.Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012 Mar;55(3):965-7. [PMC free article: PMC3378702] [PubMed: 22213561]

20.Lee WM. Acute liver failure. N Engl J Med. 1993 Dec 16;329(25):1862-72. [PubMed: 8305063]

21.Muñoz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis. 1993 Nov;13(4):395-413. [PubMed: 8303321]

22.Butterworth RF. Hepatic encephalopathy in alcoholic cirrhosis. Handb Clin Neurol. 2014;125:589-602. [PubMed: 25307598]

23.Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, Merli M, Riggio O. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2017 Jun;15(6):934-936. [PubMed: 27816756]

24.Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Ungprasert P. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol. 2020 May-Jun;19(3):245-250. [PubMed: 31422030]

25.Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012 May;16(2):301-20. [PubMed: 22541700]

26.Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, Tourbah A, Pidoux B, Valla D, Opolon P. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001 Feb;96(2):515-8. [PubMed: 11232699]

27.STAHL J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Intern Med. 1963 Jan;58:1-24. [PubMed: 13978712]

28.Montoliu C, Cauli O, Urios A, ElMlili N, Serra MA, Giner-Duran R, González-Lopez O, Del Olmo JA, Wassel A, Rodrigo JM, Felipo V. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol. 2011 Sep;106(9):1629-37. [PubMed: 21483460]

29.Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology. 1978 Sep;75(3):462-9. [PubMed: 680502]

30.Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Merkel C, Gerunda G, Gatta A. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun;29(6):1662-7. [PubMed: 10347105]

31.Amodio P, Marchetti P, Del Piccolo F, Campo G, Rizzo C, Iemmolo RM, Gerunda G, Caregaro L, Merkel C, Gatta A. Visual attention in cirrhotic patients: a study on covert visual attention orienting. Hepatology. 1998 Jun;27(6):1517-23. [PubMed: 9620321]

32.Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun;22(6):541-50. [PubMed: 868833]

33.Weissenborn K, Rückert N, Hecker H, Manns MP. The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol. 1998 Apr;28(4):646-53. [PubMed: 9566834]

34.Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet. 1995 Jul 29;346(8970):270-4. [PubMed: 7630246]

35.Thuluvath PJ, Edwin D, Yue NC, deVilliers C, Hochman S, Klein A. Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy. Hepatology. 1995 Feb;21(2):440-2. [PubMed: 7843718]

36.Krieger S, Jauss M, Jansen O, Theilmann L, Geissler M, Krieger D. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. Gastroenterology. 1996 Jul;111(1):147-55. [PubMed: 8698193]

37.Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis. 1996 Aug;16(3):329-38. [PubMed: 8989818]

38.Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977 Apr;72(4 Pt 1):573-83. [PubMed: 14049]

39.Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013 Jun;28(2):313-20. [PubMed: 23456517]

40.Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol. 2020 Apr;26(2):83-127. [PMC free article: PMC7160350] [PubMed: 31918536]

41.Agarwal B, Cañizares RB, Saliba F, Ballester MP, Tomescu DR, Martin D, Stadlbauer V, Wright G, Sheikh M, Morgan C, Alzola C, Lavin P, Green D, Kumar R, Sacleux SC, Schilcher G, Koball S, Tudor A, Minten J, Domenech G, Aragones JJ, Oettl K, Paar M, Waterstradt K, Bode-Boger SM, Ibáñez-Samaniego L, Gander A, Ramos C, Chivu A, Stange J, Lamprecht G, Sanchez M, Mookerjee RP, Davenport A, Davies N, Pavesi M, Andreola F, Albillos A, Cordingley J, Schmidt H, Carbonell-Asins JA, Arroyo V, Fernandez J, Mitzner S, Jalan R. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure. J Hepatol. 2023 Jul;79(1):79-92. [PubMed: 37268222]

42.Sommerfeld O, Neumann C, Becker J, von Loeffelholz C, Roth J, Kortgen A, Bauer M, Sponholz C. Extracorporeal albumin dialysis in critically ill patients with liver failure: Comparison of four different devices-A retrospective analysis. Int J Artif Organs. 2023 Sep;46(8-9):481-491. [PMC free article: PMC10483887] [PubMed: 37609875]

43.Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014 Mar;59(3):1144-65. [PubMed: 24716201]

44.European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022 Sep;77(3):807-824. [PubMed: 35724930]

45.Hopp AE, Dirks M, Petrusch C, Goldbecker A, Tryc AB, Barg-Hock H, Strassburg C, Klempnauer J, Weissenborn K, Pflugrad H. Hepatic Encephalopathy Is Reversible in the Long Term After Liver Transplantation. Liver Transpl. 2019 Nov;25(11):1661-1672. [PubMed: 31437344]

46.Naylor CD, O’Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology. 1989 Oct;97(4):1033-42. [PubMed: 2506095]

47.Du JY, Shu L, Zhou YT, Zhang L. Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis. World J Clin Cases. 2022 Oct 26;10(30):10984-10996. [PMC free article: PMC9631141] [PubMed: 36338230]

48.Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017 May 18;5(5):CD001939. [PMC free article: PMC6481897] [PubMed: 28518283]

49.Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014 Nov;174(11):1727-33. [PMC free article: PMC5609454] [PubMed: 25243839]

50.Hoilat GJ, Ayas MF, Hoilat JN, Abu-Zaid A, Durer C, Durer S, Adhami T, John S. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 May;8(1) [PMC free article: PMC8137169] [PubMed: 34006606]

51.Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992 Jul;16(1):138-44. [PubMed: 1618465]

52.Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017 Feb 23;2(2):CD008716. [PMC free article: PMC6464663] [PubMed: 28230908]

53.Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD002798. [PMC free article: PMC6483159] [PubMed: 28745801]

54.Loomba V, Pawar G, Dhar KL, Setia MS. Serum zinc levels in hepatic encephalopathy. Indian J Gastroenterol. 1995 Apr;14(2):51-3. [PubMed: 7797277]

55.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. [PubMed: 25042402]

56.Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61. [PMC free article: PMC4618040] [PubMed: 26164219]

57.Yu H, Chen Y, Jiang P. Prognostic value of hepatic encephalopathy for survival of patients with liver failure: A systematic review and meta-analysis. Ann Hepatol. 2019 Jul-Aug;18(4):607-612. [PubMed: 31085039]

58.Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol. 2020 May 14;26(18):2221-2231. [PMC free article: PMC7235207] [PubMed: 32476788]

59.Saleh ZM, Solano QP, Louissaint J, Jepsen P, Tapper EB. The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. United European Gastroenterol J. 2021 Jul;9(6):672-680. [PMC free article: PMC8281062] [PubMed: 34102040]

60.Endale Simegn A, Yaregal Melesse D, Belay Bizuneh Y, Mekonnen Alemu W. Perioperative management of patients with liver disease for non-hepatic surgery: A systematic review. Ann Med Surg (Lond). 2022 Mar;75:103397. [PMC free article: PMC8886011] [PubMed: 35242334]

61.Abbas N, Makker J, Abbas H, Balar B. Perioperative Care of Patients With Liver Cirrhosis: A Review. Health Serv Insights. 2017;10:1178632917691270. [PMC free article: PMC5398291] [PubMed: 28469455]

Disclosure: Pujyitha Mandiga declares no relevant financial relationships with ineligible companies.

Disclosure: Sharath Kommu declares no relevant financial relationships with ineligible companies.

Disclosure: Pradeep Bollu declares no relevant financial relationships with ineligible companies.